Fauna parasitoide de Phyllonorycter spp. en plantaciones de manzano de Lleida

Se ha estudiado en 1992, 1993 y 1996 la fauna parasitaria de Phyllonorycter corylifoliella (Hübner) y de Phyllonorycter mespilella (Hübner) existente en 4 parcelas de manzano situadas en la zona frutícola de Lleida. La incidencia de estas especies fue baja en todas las parcelas estudiadas. La tasa de parasitismo alcanzó valores del 35% cuando la población larvaria de las minadoras estuvo compuesta fundamentalmente por larvas del cuarto y del quinto estadios. En general, se observó una marcada preferencia por las larvas histófagas y una proporción de sexos siempre favorable a los machos. Básicamente, se encontraron las mismas especies en los distintos años y parcelas, aunque su abundancia relativa fue diferente. Las especies más abundantes y frecuentes fueron Sympiesis gordius Walker, Sympiesis sericeicornis Nees, Sympiesis acalle Walker (Eulophidae) y Pholetesor bicolor (Nees) (Braconidae).

Parasitoides de Cacopsylla pyri (L.) (= Psylla pyri (L.)) presentes en una plantación comercial de peral en Lleida no sometida a tratamientos insecticidas

Se ha seguido la evolución de las poblaciones de parasitoides de Cacopsylla pyri (L.) (= Psylla pyri (L.)) en una parcela comercial de peral de la variedad Blanquilla no sometida a tratamientos con productos insecticidas en Lleida. Se recogieron al azar semanalmente unas 150 ninfas de C. pyri desde abril a noviembre de 1991. Las ninfas fueron llevadas al laboratorio y colocadas en brotes de peral. Las momias fueron individualizadas en tubos de cristal hasta la emergencia del adulto del parasitoide. La especie parasitoide más abundante fue el encírtido Trechnites psyllae (Ruschka) (= Metallon psyllae (Ruschka)). También se encontró un encírtido hiperparasitoide, Aphidencyrtus mamitus (Walker) (= Syrphophagus mamitus Walker). Se observó un 18 % de parasitismo en la primera quincena de mayo sobre ninfas de la primera generación de C. pyri, época del año en la que no han hecho su aparición los depredadores de psylla.

Toxicity screenings of nanomaterials: challenges due to interference with assay processes and components of classic in vitro tests.

Given the multiplicity of nanoparticles (NPs), there is a requirement to develop screening strategies to evaluate their toxicity. Within the EU-funded FP7 NanoTEST project, a panel of medically relevant NPs has been used to develop alternative testing strategies of NPs used in medical diagnostics. As conventional toxicity tests cannot necessarily be directly applied to NPs in the same manner as for soluble chemicals and drugs, we determined the extent of interference of NPs with each assay process and components. In this study, we fully characterized the panel of NP suspensions used in this project (poly(lactic-co-glycolic acid)-polyethylene oxide [PLGA-PEO], TiO2, SiO2, and uncoated and oleic-acid coated Fe3O4) and showed that many NP characteristics (composition, size, coatings, and agglomeration) interfere with a range of in vitro cytotoxicity assays (WST-1, MTT, lactate dehydrogenase, neutral red, propidium iodide, (3)H-thymidine incorporation, and cell counting), pro-inflammatory response evaluation (ELISA for GM-CSF, IL-6, and IL-8), and oxidative stress detection (monoBromoBimane, dichlorofluorescein, and NO assays). Interferences were assay specific as well as NP specific. We propose how to integrate and avoid interference with testing systems as a first step of a screening strategy for biomedical NPs.

Towards an alternative testing strategy for nanomaterials used in nanomedicine: Lessons from NanoTEST.

In spite of recent advances in describing the health outcomes of exposure to nanoparticles (NPs), it still remains unclear how exactly NPs interact with their cellular targets. Size, surface, mass, geometry, and composition may all play a beneficial role as well as causing toxicity. Concerns of scientists, politicians and the public about potential health hazards associated with NPs need to be answered. With the variety of exposure routes available, there is potential for NPs to reach every organ in the body but we know little about the impact this might have. The main objective of the FP7 NanoTEST project ( www.nanotest-fp7.eu ) was a better understanding of mechanisms of interactions of NPs employed in nanomedicine with cells, tissues and organs and to address critical issues relating to toxicity testing especially with respect to alternatives to tests on animals. Here we describe an approach towards alternative testing strategies for hazard and risk assessment of nanomaterials, highlighting the adaptation of standard methods demanded by the special physicochemical features of nanomaterials and bioavailability studies. The work has assessed a broad range of toxicity tests, cell models and NP types and concentrations taking into account the inherent impact of NP properties and the effects of changes in experimental conditions using well-characterized NPs. The results of the studies have been used to generate recommendations for a suitable and robust testing strategy which can be applied to new medical NPs as they are developed.